A Medical Device Daily

Kensey Nash (Exton, Pennsylvania) said its board has approved a new stock repurchase program that allows the company to repurchase an additional $30 million of its issued and outstanding shares of common stock, in addition to roughly $3 million currently remaining under the previous repurchase program. The company said it intends to finance the repurchases using its available cash and liquid investments.

Kensey Nash said it plans to repurchase its shares for cash, from time to time in the open market, through block trades or otherwise. The repurchase program does not require the company to purchase any specific dollar value or number of shares. As of Jan. 31 the company had about 10,935,576 shares of common stock outstanding.

Kensey Nash is a medical device company primarily focused on regenerative medicine utilizing its collagen and synthetic polymer technology.